Altria has announced plans to acquire e-cigarette and vaping giant NJOY for $2.75 billion in cash just days after selling its stake in Juul Labs, another vaping company that is currently mired in legal challenges.
“We believe we can responsibly accelerate U.S. adult smoker and competitive adult vaper adoption of NJOY ACE in ways that NJOY could not as a standalone company,” said CEO Billy Gifford in a press release. “We believe the strengths of our commercial resources can benefit adult tobacco consumers and expand competition."
While Juul offers a similar set of so-called smoke-free products, it faces a number of legal challenges that Gifford noted could persist for the foreseeable future.
“Juul faces significant regulatory and legal challenges and uncertainties, many of which could exist for many years,” he said.
Some legal challenges remain, however. The deal stipulates that $500 million in cash payments are contingent upon some NJOY products getting regulatory approval.
The owner of Marlboro cigarettes continues to pitch its interest in vaping and e-cigarettes as a way to get smokers to transition to vaping alternatives.
“We are excited to add NJOY’s e-vapor intellectual property as a new platform that we believe we can build on to help more adult smokers transition to smoke-free alternatives,” said Olivier Houpert, chief innovation and product officer for Altria.
Amazon blamed "regulatory hurdles" for calling off its proposed acquisition of robot vacuum maker iRobot. Not even a Roomba could clean up the deal's antitrust scrutiny.
To celebrate Flutter Entertainment's debut on the NYSE, FanDuel CEO Amy Howe shares her thoughts on the company's plans for growth, the future of online sportsbetting, and Super Bowl Sunday.
Investopedia's Caleb Silver shares thoughts on the upcoming Fed meeting, why individual investors are still slightly skeptical, and what he's looking for from mega cap tech earnings.
Season's greetings! Tax season, that is. January 29 is the first day you can file your tax return. We walk you through each step — plus a checklist you can download.
The Q-Collar helps protect athletes from impact-related concussions. Now, the U.S. Army is evaluating if the device could help reduce traumatic brain injury cased by blast weapons.
Co-founder and executive chairman of the board at Vaxxinity Lou Reese shares how the company is working to bring vaccines for chronic illnesses like heart disease and Parkinson’s to market with an eye for accessibility.
Mario Veneroso, Kingsview Asset Management Partner, weighs in on the latest economic data and whether the market is pricing in too many rate cuts for the coming year.
